STOCK TITAN
  1. Home
  2. News
  3. OCGN

Ocugen Inc - OCGN STOCK NEWS

Welcome to our dedicated news page for Ocugen (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ocugen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ocugen's position in the market.

News
Ocugen to Present at Investing in Cures Summit
Rhea-AI Summary
Ocugen, a biotechnology company, announced that Dr. Shankar Musunuri will be a panelist at the Investing in Cures Summit 2024 to discuss therapeutic approaches for retinal diseases. The event will focus on gene agnostic strategies to address retinal disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
conferences
-
News
Ocugen Clinical Showcase Webcast Now Available
Rhea-AI Summary
Ocugen, Inc. announces the availability of the Clinical Showcase webcast discussing Phase 3 study design for OCU400, a first-in-class product candidate. The webcast features key experts sharing insights on retinitis pigmentosa and modifier gene therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.94%
Tags
none
-
News
Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit
Rhea-AI Summary
Ocugen, Inc. announced that Dr. Shankar Musunuri will present at the Abu Dhabi Family Office Summit. The event will be held in Abu Dhabi, UAE, showcasing Ocugen's presence in the biotechnology sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.21%
Tags
conferences
News
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST
Rhea-AI Summary
Ocugen, Inc. completes dosing in the first cohort of its Phase 1/2 GARDian clinical trial for OCU410ST, a gene therapy candidate for Stargardt disease, with positive feedback from leading retinal surgery centers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.26%
Tags
clinical trial
-
News
Ocugen to Present at 2024 BIO CEO & Investor Conference
Rhea-AI Summary
Ocugen, Inc. announced that Dr. Shankar Musunuri will present at the BIO CEO & Investor Conference in New York City, discussing the Company's business and clinical development strategy. The event aims to showcase recent achievements and future milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.94%
Tags
conferences
-
News
Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
Rhea-AI Summary
Ocugen, Inc. announces the start of the OCU400 Phase 3 clinical trial in early 2024 along with a Clinical Showcase event featuring gene therapy experts and patient insights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.34%
Tags
conferences
News
Ocugen to Present at Pharma Market Research Conference
Rhea-AI Summary
Ocugen, a biotechnology company, announced that Dr. Shankar Musunuri will give a keynote on gene therapy at the Pharma Market Research Conference. The event will cover diverse topics and updates on relevant trends.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
conferences
-
News
Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board
Rhea-AI Summary
Ocugen, Inc. announced the addition of Bob Smith, former Senior Vice President, Global Gene Therapy Business at Pfizer, to the Company’s Business Advisory Board. The move aims to drive public/private partnerships, business collaborations, and licensing opportunities, as well as to promote access to the Company’s therapies worldwide. Smith's experience is expected to help pursue business development activities and bring gene therapies through to commercialization. Ocugen's modifier gene therapy programs have impressed Smith, and he looks forward to introducing this novel approach to potential business partners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.51%
Tags
management
-
News
National Philanthropic Trust Welcomes Three Board Members
Rhea-AI Summary
National Philanthropic Trust (NPT) announces the appointment of Jeffrey Armbrister, Lindy Benton-Moreno, and Connie Collingsworth to its Board of Trustees. The company is now the third largest grantmaking organization in the world. Jeffrey Armbrister, Lindy Benton-Moreno, and Connie Collingsworth bring extensive experience in private market investing, technology, law, and philanthropy to the board. Jeffrey Armbrister is the CFO of Hamilton Lane (NASDAQ: HLNE), with 25+ years of investing experience. Lindy Benton-Moreno is a healthcare IT leader and Executive Board Chair of Vyne. Connie Collingsworth has vast experience in governance, risk management, and executive compensation, having served as COO of the Bill & Melinda Gates Foundation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.25%
Tags
management
News
Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design
Rhea-AI Summary
Ocugen, Inc. (NASDAQ: OCGN) Receives FDA Alignment for Phase 3 Clinical Trial Design for OCU400 Gene Therapy in Patients with Retinitis Pigmentosa
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.84%
Tags
clinical trial
Stock OCGN logo
Ocugen Inc

Nasdaq:OCGN

OCGN Rankings

#3399 Ranked by Market Cap
#5296 Ranked by Stock Gains
N/A Ranked by Dividends

OCGN Stock Data

438.79M
252.38M
1.45%
10.33%
16.95%
Sanitary Paper Product Manufacturing
Manufacturing
Link
US
Malvern

About OCGN

ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.